for educational and safety purposes
Choline sources and acetylcholine-boosting compounds; the raw material most nootropic stacks are built on.
23 sourced · 64 reference
Alpha-GPC (L-alpha glycerylphosphorylcholine) is a highly bioavailable choline source that readily crosses the blood-brain barrier to supply the raw material for acetylcholine, the neurotransmitter central to memory, focus, and muscular power. Clinical and meta-analytic evidence supports its use for cognitive performance, making it one of the most reliable cholinergic nootropics available [1][2]. It additionally potentiates growth hormone release and is widely used across both cognitive and athletic supplementation [4][5].
Choline is an essential nutrient that the body needs for building cell membranes, making the neurotransmitter acetylcholine, and supplying methyl groups used in metabolism [1][2]. Chemically it is a small water-soluble molecule, a quaternary ammonium compound, found in foods such as eggs, liver, meat, fish, and soybeans [1][2]. The body can make a little choline in the liver, but most people must obtain it from the diet, and it was formally recognized as an essential nutrient in 1998 [1][2]. Adequate choline is especially important during pregnancy for fetal brain development [3].
Coluracetam has the most distinctive proposed mechanism in the racetam family. Rather than acting at a receptor, it was designed to raise the rate at which neurons take up choline, the raw material the brain uses to build acetylcholine. Mitsubishi developed it in Japan in the 1990s as an Alzheimer's candidate, and it was later carried into depression research and through a completed 115-person trial. Readers who use it describe sharper focus and, unusually for a nootropic, changes in visual vividness. The evidence for the mechanism is narrower than the reputation: the choline-uptake effect was shown in animals whose cholinergic neurons had been deliberately lesioned first and not in normal tissue, and an independent group at Pfizer testing the same transporter across four separate methods found no effect at all. That lesion-dependence is itself worth understanding, because it would predict a quieter effect in a healthy brain rather than none. No human trial has yet reported a cognitive result; the 2009 study completed without publishing its outcomes.
Galantamine is a plant-derived alkaloid, isolated from snowdrops and related plants of the Amaryllidaceae family, used to treat the memory and thinking difficulties of mild-to-moderate Alzheimer's disease. It has an unusual dual action on the cholinergic system: it inhibits the enzyme acetylcholinesterase, and it separately acts as an allosteric potentiating ligand that binds a site distinct from the neurotransmitter's on nicotinic acetylcholine receptors, making them respond more strongly to acetylcholine. Marketed under names such as Razadyne and Reminyl, it has also been studied as a nerve-agent countermeasure and, more curiously, as an aid to lucid dreaming.
Huperzine A is a naturally occurring alkaloid isolated from the Chinese club moss Huperzia serrata, a plant long used in traditional Chinese medicine. It is a potent, selective, and long-acting reversible inhibitor of acetylcholinesterase, and it additionally acts as a non-competitive antagonist of the NMDA glutamate receptor at one of the polyamine binding sites, a combination that has made it of interest for memory, dementia, and neuroprotection. In China it is used as an approved drug, whereas in the United States it is sold as a dietary supplement.
Nefiracetam is a fat-soluble pyrrolidinone racetam that modulates cholinergic, glutamatergic, and calcium signaling. It potentiates neuronal nicotinic acetylcholine receptor currents at sub-nanomolar concentrations and enhances NMDA-receptor function and long-term potentiation through protein kinase C and CaMKII, giving it a pronounced pro-cognitive and neuroprotective profile in preclinical research; it has also been reported to reverse signaling deficits in a laboratory model of Rett syndrome. It has been studied for memory impairment, dementia, and post-stroke apathy and depression.
Fasoracetam is a racetam-class nootropic that acts on the glutamatergic and GABAergic systems; with repeated administration it up-regulates GABA-B and metabotropic glutamate (mGluR) receptors. It is one of relatively few racetams to have reached controlled human trials, having been evaluated in adolescents with attention-deficit hyperactivity disorder who carry variants in genes governing mGluR signaling. It remains an investigational compound and is not an approved medicine.
CDP-choline (citicoline, cytidine diphosphate-choline) is a naturally occurring compound that the body uses as an intermediate in making phosphatidylcholine, a major building block of cell membranes. Taken as a drug or dietary supplement, it supplies choline and cytidine to the brain and is studied for cognition, stroke recovery, and certain eye conditions. It is sold as a prescription medicine in some countries and as an over-the-counter supplement in others.
Donepezil is a medication used to treat the symptoms of dementia in Alzheimer's disease. It belongs to a class of drugs called cholinesterase inhibitors, which work by boosting levels of the signaling chemical acetylcholine in the brain. Developed by the Japanese company Eisai and approved in the United States in 1996 under the brand name Aricept, it is one of the most widely prescribed treatments for Alzheimer's dementia. Donepezil eases symptoms modestly but does not stop or reverse the underlying disease.
PRL-8-53 is a classic research nootropic famous for a single striking human study in which low oral doses significantly improved the retention of newly learned verbal information [1]. Chemically a methyl benzoate compound developed in the 1970s, it was reported to sharpen memory while potentiating the brain's dopaminergic and stimulant signaling [1][2]. Its reputation rests almost entirely on that early double-blind trial, as PRL-8-53 has never been independently replicated or brought to market, and it remains an obscure but intriguing research chemical [1][2].
Tropisetron is a prescription anti-nausea drug that blocks the serotonin 5-HT3 receptor, and it is used to stop the vomiting caused by chemotherapy or by surgery; it has been sold for that purpose since 1992 in Europe, Japan, Australia and much of Asia, but it was never approved in the United States. What sets it apart from the other drugs in its class is that it also binds tightly to a brain receptor called the alpha-7 nicotinic acetylcholine receptor, which is why researchers have tested it for fibromyalgia pain, for thinking problems in schizophrenia, and in animal models of Alzheimer's and Huntington's disease. The anti-nausea use is solidly established; every other use rests on small short trials, mostly fewer than 45 people and under two weeks long, or on animal work, and no regulator anywhere has approved it for any of them. Anyone reading the older literature should also know that a large slice of the post-surgical anti-nausea evidence base was fabricated and later retracted, so individual old trials in that area carry very little weight on their own.
Choline bitartrate is a salt of the essential nutrient choline combined with tartaric acid, widely used as an inexpensive dietary supplement to boost choline intake [1][2]. Because choline supports cell membranes, the neurotransmitter acetylcholine, and methyl-group metabolism, the bitartrate form is taken to help meet the body's need for the nutrient [1][3]. It is a common choice in supplements, valued for being stable and absorbing little moisture, and it delivers choline for the same functions as choline from food [1]. As with choline generally, very high intakes can cause side effects such as a fishy body odor [1].
cytisine (tabex, cytisinicline) is a natural plant-alkaloid nicotinic partial agonist and the structural parent of varenicline; a high-affinity alpha4beta2 partial agonist, high-efficacy alpha3beta4 agonist, and only a weak partial agonist at the alpha6beta2* dopamine-terminal receptors that gate nicotine reward; a cheap, trial-validated smoking-cessation drug rather than a nootropic.
Dimethylaminoethanol (DMAE), also known as deanol or dimethylethanolamine, is an organic amino alcohol with the formula (CH3)2NCH2CH2OH. Structurally it resembles the nutrient choline, differing by one methyl group on its nitrogen atom, and it is chemically related to the neurotransmitter acetylcholine. Alongside a range of industrial uses, DMAE is sold as a dietary supplement promoted for cognition and mood and is used as an ingredient in skin-firming cosmetics, although the evidence for many of its claimed effects is limited.
Ipidacrine is a genuine Cold War-era Soviet original, synthesized at the National Research Center for Biologically Active Compounds in Russia and pushed through the 1970s and 1980s under the code name NIK-247, decades before it ever appeared on a Western researcher's radar. Rather than working through the single acetylcholinesterase-inhibition mechanism most of its Western contemporaries relied on, it combines that AChE blockade with direct potassium-channel blockade at nerve and muscle membranes, a dual action that boosts both central cholinergic tone and peripheral nerve-impulse conduction. It remains sold and prescribed today in Russia and several post-Soviet states as Neuromidin (also called Amiridin or, in a topical form, Axamon), for memory disorders and peripheral nerve conditions, but it never went through Western-style FDA or EMA trials and stayed essentially invisible outside that regulatory sphere, a working drug that the rest of the world simply never met.
nicergoline (sermion) is a semisynthetic ergoline nootropic-vasodilator; a potent alpha-1 blocker that also boosts cholinergic/neurotrophic tone, with modest but real cochrane-backed benefit in age-related and vascular cognitive decline, tempered by ergot-class fibrosis risk on long timelines.
Phosphatidylcholine is a class of phospholipids that form a major part of the membranes surrounding living cells and are the principal component of lecithin. Each molecule is built from a glycerol backbone, two fatty acids, and a phosphate group linked to choline, and the compound is abundant in foods such as egg yolk and soybeans. Beyond its structural role, phosphatidylcholine is the body's main store of the essential nutrient choline and has been studied as a dietary supplement and in conditions ranging from liver disease to ulcerative colitis.
Piritinol, also spelled pyritinol and known as pyrithioxine, is a semisynthetic derivative of vitamin B6 (pyridoxine) that has been used as a nootropic and cerebral-function agent since the 1960s. It is built from two pyridoxine molecules linked by a disulfide bridge, a change that alters how the molecule behaves compared with the parent vitamin. In several European countries it is prescribed for chronic cognitive impairment and as supportive care after head trauma, and it has also been sold as a dietary supplement in some markets.
Uridine monophosphate (UMP) is the nucleotide form of uridine and the most common way uridine is sold as a nootropic. It feeds the pathway that builds neuronal membranes and supports acetylcholine and dopamine signaling; it is the uridine in the popular Mr Happy stack alongside omega-3s and a choline source.
Uridine triacetate is a prodrug of uridine; three acetate groups make it far more orally bioavailable than plain uridine, so it delivers much more uridine to the body and brain. It is used both clinically (as Vistogard/Xuriden) and popularly in nootropic uridine stacks for memory and mood.
Pramiracetam is a laboratory-made compound in the piracetam ("racetam") family, developed by Parke-Davis as CI-879 and later sold in a few European countries as a prescription memory drug under the brand name Pramistar. It is meant to improve memory and attention; in animals it reliably increases the rate at which brain cells take up choline, a building block of the memory-related signalling chemical acetylcholine, but no receptor that it binds to has ever been identified. Human evidence is thin: a small placebo-controlled trial in men with head injuries reported better delayed recall, and a study in healthy volunteers found it partly blunted drug-induced forgetting, while a trial in Alzheimer's disease found no benefit even at high doses. The entire published literature is roughly 40 papers, most of them small, decades old, or done in rodents, so confident claims that it strongly enhances cognition in healthy people are not supported by what has actually been measured.
Bethanechol is a parasympathomimetic drug that acts as an agonist at muscarinic acetylcholine receptors. It is used chiefly to stimulate the bladder and, less often, the gastrointestinal tract, most commonly to relieve non-obstructive urinary retention when the bladder muscle fails to contract properly [1]. Because it resists breakdown by the enzyme that normally inactivates acetylcholine, its effect lasts far longer than the natural neurotransmitter. It is a prescription medicine sold under brand names such as Urecholine, although its clinical usefulness is considered modest [2].
Pilocarpine is a muscarinic cholinergic agonist, a parasympathomimetic drug originally extracted from the leaves of Pilocarpus (jaborandi) shrubs native to Brazil. In the eye it constricts the pupil and lowers pressure, so it has long been used for glaucoma and, more recently, in low-dose drops for the age-related loss of near vision known as presbyopia. Taken as a tablet it stimulates the salivary glands and is used to relieve dry mouth caused by Sjögren syndrome or radiation therapy.
522-054 is a laboratory research compound built in Kelvin Gee's group at the University of California, Irvine to do two opposite things to the hippocampus at once: strengthen α7 nicotinic acetylcholine receptors and block the α5-subunit-containing GABA-A receptors that hold pyramidal cells under constant inhibition. In rats the combination potentiated synapses, lowered the threshold for long-term potentiation, and restored learning and attention that had been disrupted either by scopolamine or by a traumatic brain injury months earlier. The whole published record is two primary papers, both in rats and rat tissue, plus one review that summarises them. No human has been given it and no clinical trial exists.
ABT-089, also known as pozanicline, is a synthetic small molecule that acts as a partial agonist at neuronal nicotinic acetylcholine receptors, with selectivity for the α4β2 subtype. Developed by Abbott Laboratories, it was investigated as a cognitive enhancer and as a candidate treatment for attention-deficit/hyperactivity disorder (ADHD) and other cognitive conditions.
ABT-126 was AbbVie's (formerly Abbott's) selective alpha7 nicotinic acetylcholine receptor agonist, developed for both cognitive impairment in schizophrenia and Alzheimer's disease. The alpha7 receptor is heavily expressed on hippocampal and prefrontal circuits involved in learning and attention, and it was a hot target through the 2010s after epidemiological observations tied smoking to modest cognitive benefits in schizophrenia patients. A Phase 2 trial found a real procognitive signal, but only in nonsmokers; smokers, whose alpha7 receptors were presumably already saturated or desensitized by nicotine, showed nothing. A larger Phase 2b confirmatory trial in nonsmokers, and a separate one in smokers, both failed to show meaningful benefit, and AbbVie discontinued the program around 2016 along with much of the industry's broader retreat from alpha7 agonists.
AC-260584 is an Abbott Laboratories research compound from the 2000s, part of the same M1-muscarinic-agonist wave as sabcomeline and xanomeline but never carried past the tool-compound stage. It was designed as an orally bioavailable, functionally selective M1 agonist that improved cognitive performance in animal testing while sidestepping the receptor subtypes responsible for the GI and cardiac side effects that plagued earlier muscarinic drugs. Unlike some of its contemporaries, AC-260584 does not appear to have been pushed into human trials; its public record is essentially one core pharmacology paper, making it a compound that lives almost entirely in the preclinical literature.
Adafenoxate is a little-known nootropic that is essentially the adamantane version of meclofenoxate (centrophenoxine). Like its parent it pairs an ester carrier with DMAE (dimethylaminoethanol), a choline-related molecule tied to acetylcholine and to membrane maintenance, but swaps the parent's chlorophenoxyacetic acid for a bulky adamantane group. Almost all of what is known comes from a cluster of Bulgarian rodent studies from the late 1980s and early 1990s, where it behaved like a cholinergic, monoamine-modulating, memory-protective agent. There is essentially no modern or human data, so it is a research curiosity rather than an established supplement.
alpha-conotoxin mii is a cone-snail peptide toxin and the foundational research probe for alpha6-containing nicotinic receptors; native mii blocks both alpha3beta2 and alpha6* subtypes, but engineered analogs (mii[h9a;l15a], mii[s4a,e11a,l15a]) reach ~590-1000-fold alpha6 selectivity at low-nanomolar potency; a lab tool, not a drug, but the one that unlocked alpha6* dopamine-terminal pharmacology.
alpha-conotoxin pia is a cone-snail (conus purpurascens) peptide toxin and the first ligand able to cleanly discriminate alpha6- from alpha3-containing nicotinic receptors; a highly alpha6beta2*-selective research probe that sharpened the interpretation of 'mii-sensitive' dopamine and gaba experiments; a lab reagent, not a drug.
alpha-conotoxin txib is a conus textile peptide toxin and one of the most selective alpha6/alpha3beta2beta3 nicotinic antagonists known (rat ic50 ~28 nm, sparing other rat subtypes), with a human alpha6/alpha3beta4 off-target as a species-difference caveat; a clean research probe and drug-design lead for addiction and parkinson's, not a therapeutic in itself.
Alvameline was Lundbeck's attempt at a smarter cholinergic drug for Alzheimer's disease. Rather than pushing every muscarinic receptor at once, the way older agonists did, it was built to be a partial agonist at M1, the postsynaptic receptor thought to carry the cholinergic signal for memory, while blocking M2 and M3, the receptors behind the presynaptic brake and behind most of the salivation, sweating and gut cramping that had sunk earlier compounds. In animals the design held up: it produced none of the tremor, hypothermia or drooling that non-selective agonists cause in mice, and it read as its own thing in drug discrimination rather than as a copy of either a full agonist or a cholinesterase inhibitor. The clinic went the other way. A six-month trial across 29 centres randomised 496 people with probable Alzheimer's disease to placebo or 25, 50 or 100 mg three times daily and found nothing on either primary endpoint; among completers the highest dose actually trended worse, and side effects still climbed with dose. Development stopped. The molecule had a brief second life as a candidate bladder antimuscarinic, where the M3 blockade was the point rather than a design compromise, and nothing came of that either.
an6001 is an experimental (saniona) positive allosteric modulator that is selective for alpha6beta2-containing nicotinic receptors; it boosts nicotine's potency and efficacy at alpha6/alpha3beta2beta3 (ec50 ~0.58 uM) without touching alpha4beta2/alpha3beta4/alpha7/muscle, augments striatal dopamine release and nigral neuron activity, and potentiates nicotine's neuroprotection in a parkinson's model; a preclinical tool and proof that alpha6-selective small molecules exist, not a medicine.
AQW051 was Novartis's alpha7 nicotinic acetylcholine receptor partial agonist, developed alongside ABT-126, TC-5619, and encenicline in the industry-wide push to translate the alpha7 receptor's role in hippocampal and prefrontal circuits into a working schizophrenia cognition drug. Novartis took an unusually mechanistic approach to testing it, using functional MRI in a randomized crossover trial to watch how the drug changed brain activation during working-memory and episodic-memory tasks in people with chronic, stable schizophrenia, rather than relying on behavioral scores alone. The imaging trial found AQW051 did alter neuronal activity in prefrontal and hippocampal regions, but it did not translate into a consistent cognitive benefit, and in smokers at higher doses working memory performance seemed to get worse rather than better. Combined with the broader wave of alpha7 agonist failures across the industry, Novartis did not carry AQW051 forward into larger confirmatory trials.
Bifemelane (brand names Alnert and Celeport; development code MCI-2016) is a Japanese cerebral activator and antidepressant that acted mainly as a reversible, competitive inhibitor of monoamine oxidase type A, with weaker noncompetitive inhibition of MAO-B [1]. It was prescribed in Japan from the late 1980s for the emotional and cognitive disturbances that follow cerebral infarction [6], and was also trialed in glaucoma [9]. Most of its evidence comes from small Japanese studies from the 1980s and 1990s; it was pulled from the market in 1998 after a national re-evaluation judged the effectiveness of that whole class of cerebral metabolic enhancers to be unproven.
A non-selective cholinergic agonist that acetylcholinesterase cannot readily break down; in United States practice it survives as an ophthalmic drug, and in the laboratory as one of the most heavily used tools in cholinergic pharmacology.
An oral muscarinic agonist approved in the United States in 2000 for the symptoms of dry mouth in Sjogren's syndrome, where it drives whatever secretory tissue the disease has left.
Cytidine is a pyrimidine nucleoside made up of the base cytosine joined to a ribose sugar. It is one of the fundamental building blocks of RNA, where its phosphorylated forms act as nucleotides, and it also feeds into the synthesis of cell membrane phospholipids. In humans, dietary and supplemental cytidine is largely converted to the related nucleoside uridine, and it is closely tied to the choline donor CDP-choline (citicoline); it has additionally been studied in a small way for mood disorders.
A selective M4 positive allosteric modulator built at Pfizer and carried into schizophrenia trials by Cerevel and then AbbVie, whose phase 2 programme failed to beat placebo in November 2024.
Encenicline (EVP-6124) is an investigational, orally active, selective partial agonist of the alpha7 nicotinic acetylcholine receptor developed for cognitive impairment in schizophrenia and Alzheimer disease. Late-stage clinical development was halted after serious gastrointestinal adverse events, and it is not approved for any use.
Eptastigmine was the Italian pharmaceutical company Mediolanum's long-acting redesign of physostigmine, an old carbamate cholinesterase inhibitor whose natural form works but wears off too fast to dose conveniently; adding a heptyl (seven-carbon) chain extended its duration of action enough to make once- or twice-daily dosing plausible for Alzheimer's patients. It moved through a full decade of pharmacology, toxicology, and clinical study, including efficacy trials that showed genuine cognitive benefit over placebo. Then hematology data caught up with it, reversible neutropenia and, in a subset of patients, agranulocytosis (a dangerous collapse in infection-fighting white blood cells) showed up during clinical trials at a rate high enough that regulators would not accept the risk, and the program was discontinued despite a decade of otherwise promising work.
GSK1034702 is a GlaxoSmithKline benzimidazolone marketed in the literature as an M1 allosteric agonist; it improved immediate recall in nicotine-abstinent smokers and was later shown to bind M1 bitopically and to lack muscarinic subtype selectivity.
GTS-21, also known as DMXB-A, is an investigational drug that acts as a selective partial agonist at the alpha-7 subtype of nicotinic acetylcholine receptors. It is a synthetic derivative of anabaseine, a natural compound found in certain marine worms, and was developed as a candidate treatment for the cognitive problems of conditions such as schizophrenia and Alzheimer's disease [1][2]. Despite encouraging early laboratory results, it has not shown clear clinical benefit and has not advanced beyond mid-stage trials [2].
A selective M1 partial agonist from Heptares that improved memory and attention in healthy volunteers and Alzheimer's patients, and was halted in 2018 over a tumour finding in monkeys rather than anything seen in people.
Idalopirdine is a potent, selective serotonin 5-HT6 receptor antagonist developed by H. Lundbeck (as Lu AE58054) as an adjunctive symptomatic treatment for Alzheimer's disease. By blocking 5-HT6 receptors, which are expressed almost exclusively in the central nervous system and concentrated in the hippocampus and cortex, it disinhibits cholinergic, glutamatergic and monoaminergic transmission relevant to memory. A phase 2 trial (LADDER) in donepezil-treated moderate Alzheimer's disease showed a significant cognitive benefit, but the larger phase 3 STARSHINE, STARBEAM and STARBRIGHT programme failed to replicate it. Idalopirdine is discontinued for cognition and is now referenced primarily as a pharmacological tool and cautionary case study.
Intepirdine is a selective serotonin 5-HT6 receptor antagonist originally discovered at GlaxoSmithKline as SB-742457 and later licensed to Axovant Sciences as RVT-101 for Alzheimer's disease and dementia with Lewy bodies. Like other compounds in its class it was intended to enhance cognition by disinhibiting cholinergic and glutamatergic signaling in cortex and hippocampus. A phase 2 study suggested a modest global and cognitive benefit, but the pivotal phase 3 MINDSET trial in mild-to-moderate Alzheimer's disease was clearly negative. Its high-profile failure in 2017 effectively ended enthusiasm for 5-HT6 antagonism as a standalone dementia strategy.
Ispronicline traces its chemistry back to nicotine research originally funded by tobacco company R.J. Reynolds, which spun off its pharmaceutical research arm into Targacept in the late 1990s. The resulting compound was a partial agonist at alpha4beta2 neuronal nicotinic receptors, designed to capture nicotine's attention- and memory-enhancing effects without its addictive and cardiovascular baggage. AstraZeneca partnered with Targacept and pushed ispronicline (as AZD3480) into a Phase IIb dose-finding trial for mild-to-moderate Alzheimer's disease as well as separate studies for adult ADHD. The Alzheimer's trial, published in 2011, failed to show a robust cognitive benefit, and AstraZeneca discontinued the partnership around 2010-2011, part of a broader collapse of the nicotinic-receptor cognition-enhancement field that also claimed several competing programs.
L-Clausenamide, or (-)-clausenamide, is a pyrrolidinone alkaloid isolated from the leaves of Clausena lansium (wampee) and studied in China as a nootropic and neuroprotective anti-dementia drug candidate [1]. It is the eutomer of the clausenamide enantiomers, improving learning and memory through multi-target actions including modulation of intracellular calcium, cholinergic support, enhancement of synaptic plasticity and long-term potentiation, and antioxidant protection [1]. In cellular and animal models it protects neurons against beta-amyloid, okadaic-acid and ischemic injury and inhibits ferroptosis in dopaminergic neurons [2][3][4].
Linopirdine took a completely different route to boosting acetylcholine than anything else in this collection; instead of blocking the enzyme that breaks ACh down, DuPont built it to block KCNQ2/KCNQ3 potassium channels, the so-called M-channel, which in turn triggers broad neurotransmitter release, acetylcholine included, across the brain. Preclinical work in the late 1980s looked strong enough that DuPont pushed it into Alzheimer's clinical trials, but the results in patients were equivocal; the drug needed high doses to meaningfully block the M-current, and those doses caused cholinergic overstimulation side effects like tremor. The program was ultimately discontinued, but linopirdine's real legacy is scientific rather than commercial, it became the founding tool compound for an entire generation of KCNQ channel research, directly enabling more selective descendants like XE-991 and eventually helping validate KCNQ as a target that led to the anticonvulsant retigabine.
LY2033298 is a preclinical positive allosteric modulator of the M4 muscarinic acetylcholine receptor; it was the first small molecule selective enough to test whether activating M4 on its own could produce an antipsychotic effect.
Masupirdine is a potent, selective serotonin 5-HT6 receptor antagonist developed by Suven Life Sciences as SUVN-502 for cognitive deficits in Alzheimer's disease. It was distinctive as the first compound in its class tested on a background of both donepezil and memantine, reflecting real-world moderate Alzheimer's disease management. The pivotal phase 2 proof-of-concept study did not meet its prespecified cognitive endpoint, although exploratory post hoc analyses suggested that concurrent memantine may have masked a benefit. Suven has since pivoted masupirdine toward agitation in dementia rather than core cognition.
McN-A-343 is a quaternary muscarinic agonist that served for decades as the standard tool for identifying M1-mediated responses, and which is now understood to owe that apparent selectivity to uneven efficacy and to a second, allosteric binding site rather than to selective binding.
Meclofenoxate, also known as centrophenoxine, is a nootropic compound classified as a cholinergic agent, made by combining dimethylethanolamine (DMAE) with para-chlorophenoxyacetic acid. Developed in the late 1950s, it has been used, mainly in Europe and Asia, as a prescription drug for age-related cognitive decline and dementia, and it is sold elsewhere as an unapproved dietary supplement marketed for memory and mental alertness [1][4]. Research, much of it older or preclinical, has examined its effects on memory, brain aging, and the accumulation of the cellular waste pigment lipofuscin [2].
A short-acting inhaled muscarinic agonist used for exactly one job, the bronchial challenge test, which measures whether a person's airways narrow more readily than they should.
Methylphenylpiracetam (MPP) is a methylated analogue of phenylpiracetam developed at the Latvian Institute of Organic Synthesis, and its most studied stereoisomer, E1R, is a positive allosteric modulator of the sigma-1 receptor [1]. In mice, E1R enhances memory retention and reverses scopolamine-induced cognitive impairment without altering locomotor activity, effects abolished by the selective sigma-1 antagonist NE-100 [1]. Unlike its parent phenylpiracetam, which is primarily a dopaminergic psychostimulant, MPP is characterized as a non-stimulant cognition enhancer acting through sigma-1 chaperone signaling [1].
Metrifonate has one of the stranger backstories in Alzheimer's drug history; it started life decades earlier as an antischistosomal insecticide-derived organophosphate sold as Bilarcil, and only later did researchers realize its slow, pseudo-irreversible acetylcholinesterase inhibition made it a candidate for boosting acetylcholine in Alzheimer's disease. Bayer ran it through large placebo-controlled Phase III trials where it produced genuine, statistically significant cognitive improvement over placebo, real efficacy that few of its competitors in this archive ever achieved. Then, deep into trials, roughly twenty patients developed neuromuscular dysfunction and life-threatening respiratory paralysis, apparently related to how chronic organophosphate exposure sensitizes patients to subsequent anesthetic or neuromuscular-blocking agents; Bayer halted the program and withdrew its FDA application in 1997, turning a drug with real cognitive benefit into a cautionary tale about repurposing organophosphates for chronic dosing.
Milameline was Parke-Davis and Roussel-Uclaf's shot at treating Alzheimer's disease by stimulating muscarinic receptors directly instead of propping up acetylcholine with a cholinesterase inhibitor. It is a partial agonist with roughly equal affinity at all five muscarinic subtypes, which was the deliberate choice: no subtype selectivity, just enough intrinsic activity to signal without saturating the system. The preclinical package was strong for its era. It reversed spatial memory deficits in rats with lesioned forebrain cholinergic neurons, raised cortical blood flow, desynchronised the EEG in both rats and rhesus monkeys in the pattern that reads as increased arousal, and rescued scopolamine-impaired attention in monkeys. Then the dose window closed. In Alzheimer's patients, 1 mg every six hours was fine, 2 mg was tolerated by most people, and 2.5 to 3 mg brought sweating, hypersalivation, nausea, diarrhoea, hypotension and, notably, parkinsonian signs including cogwheeling, tremor and a shuffling gait; that study was stopped after the fourth 3 mg dose. The pivotal 52-week trial across 38 centres was then terminated early when an interim analysis projected it would not work. It never worked, and it was never approved.
MK-7622 is a Merck M1-selective muscarinic positive allosteric modulator that reached a phase 2 Alzheimer's trial as an add-on to acetylcholinesterase inhibitors and was stopped at a futility interim analysis.
The fungal alkaloid that muscarinic receptors are named after; it has no therapeutic use and matters today as the toxin behind Inocybe and Clitocybe mushroom poisoning.
Nebracetam (development code WEB 1881 FU) is an investigational nootropic of the racetam family that was studied mainly in Japan as a potential cognition enhancer. Chemically a pyrrolidinone related to piracetam, it is distinguished from most racetams by acting as a direct agonist at the M1 muscarinic acetylcholine receptor, alongside pronounced cholinergic and neuroprotective effects in preclinical models of memory impairment and cerebral ischemia. It was explored in such models but did not become an approved medicine.
NGX267 started life at Neurogen Corporation and was carried forward by TorreyPines Therapeutics in the mid-to-late 2000s as a dual M1/M4 muscarinic agonist with two proposed uses: improving cognition in Alzheimer's disease and treating xerostomia (severe dry mouth), a side effect common in Sjogren's syndrome and antipsychotic treatment. Its first-in-human dose-escalation study, published in 2009, used an adaptive statistical design that ended up getting cited almost as often for its methodology as for the drug itself. TorreyPines' broader pipeline stalled soon after, the company dissolved and merged into Raptor Pharmaceutical around 2009-2010, and NGX267 was left without a sponsor to carry it into later-phase trials.
nicotine is a genuinely nootropic nicotinic agonist with a small, real, meta-analysis-backed edge on attention and psychomotor speed (bigger in cholinergic-deficit brains than in healthy young ones), delivered through α4β2, α6 and α7 receptors; the honest catch is that it's an addictive drug whose habit-forming power scales with how fast you take it, so the entire case for using it rests on non-combusted low-dose delivery and clear eyes about dependence.
Oxotremorine is a non-selective muscarinic agonist used in the laboratory to produce a reproducible cholinergic syndrome in rodents: tremor, hypothermia, salivation and analgesia.
PF-06827443 is a Pfizer M1-selective positive allosteric modulator designed to test whether M1 modulation without agonist activity could avoid cholinergic toxicity; it produced cholinergic adverse events and convulsions in animals anyway.
PNU-120596 is a selective type II positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor; it raises channel open probability and destabilizes receptor desensitization to amplify cholinergic signaling without directly activating the receptor. It is an investigational research tool used to probe alpha7 mechanisms in cognition, schizophrenia and inflammation, and is not approved for human use.
A selective M1 positive allosteric modulator from Merck, used as the reference preclinical tool for the claim that boosting acetylcholine at M1 alone improves cognition without the gut effects of a cholinesterase inhibitor.
A Pfizer M1 positive allosteric modulator whose tritiated form became the first radioligand for the M1 allosteric site, letting a program rank modulators by how tightly they bind instead of only by what they do.
Sabcomeline was SmithKline Beecham's most clinically advanced muscarinic-agonist candidate for Alzheimer's disease, marketed in development under the name Memric, and it made it further than most of its rivals in this slice, all the way to Phase III. It bound all five muscarinic receptor subtypes with similar raw affinity but showed functional selectivity for M1 in both cell assays and animal behavior, reversing delay-induced memory deficits in marmosets and rats at doses well below those that triggered cholinergic side effects. Despite genuinely promising early signals of symptomatic benefit in Alzheimer's patients without provoking overt cholinergic toxicity, the Phase III program ultimately produced disappointing results and SmithKline Beecham shelved it, one more entry in the long list of muscarinic-agonist Alzheimer's drugs that looked good on paper and in monkeys but not in a pivotal trial.
Sabeluzole (R 58 735) is a benzothiazole derivative developed by Janssen Pharmaceutica as a neuroprotective memory enhancer. In controlled studies it improved learning and recall in healthy elderly volunteers and showed signs of stabilizing cognition in Alzheimer's disease over a year of treatment. Its actions are attributed to modulation of sodium channels, protection against glutamate excitotoxicity and anoxia, and effects on fast axonal transport. Development was ultimately discontinued, but it remains a notable historical cognition-focused neuroprotectant.
Sapunifiram (MN-19) is an investigational piperidine cognition-enhancer developed by the medicinal chemistry group at the University of Florence as a close structural relative of sunifiram (DM235). Like its parent scaffold, it produces potent antiamnesic and procognitive effects in rodent avoidance paradigms at very low doses, with reported potency exceeding that of piracetam. It is best understood as an ampakine-like glutamatergic and cholinergic facilitator rather than a classical racetam, and it has never advanced beyond preclinical characterization. It remains a purely research-grade compound of interest to structure-activity chemists and the nootropic community.
SB-399885 is a potent, selective and orally active serotonin 5-HT6 receptor antagonist developed at GlaxoSmithKline as a cognition-enhancer research compound. It has very high 5-HT6 affinity and more than 200-fold selectivity over other receptors, ion channels and enzymes, making it one of the cleaner pharmacological probes for the receptor. In rodent studies it reversed scopolamine- and dizocilpine-induced memory deficits, improved spatial learning in aged rats and raised cortical acetylcholine. It was never marketed but is a well-validated tool antagonist widely used to test the 5-HT6 cognition hypothesis.
A Takeda M1 positive allosteric modulator built deliberately weak at amplifying acetylcholine, made to test whether a low cooperativity ceiling is what separates a procognitive effect from cholinergic side effects.
T-588 came out of Toyama Chemical in Japan as a multi-target cognitive enhancer built for the vascular-dementia and post-stroke cognitive-impairment niche that Japanese pharma researched heavily in the 1990s, a market segment Western companies mostly ignored. Rather than hitting one clean receptor, it increased acetylcholine and noradrenaline release in the cortex and hippocampus, blocked an outward potassium current in CA1 neurons, and protected cerebellar granule cells from glutamate excitotoxicity, a genuinely broad-spectrum profile aimed at both boosting transmission and shielding neurons from ischemic damage. It compensated for scopolamine-induced learning impairment and improved working memory after simulated cerebral ischemia in rodents, but like most Japanese vascular-cognition compounds of its era, it never crossed into Western regulatory pipelines and faded from view once academic interest moved to other neuroprotective targets.
A Takeda M1 positive allosteric modulator aimed at constipation rather than cognition; it amplifies the enteric nervous system's own acetylcholine signaling to produce coordinated, propagating colonic contractions.
Tacrine earns its spot in this archive on historical weight rather than obscurity; it was the first drug the FDA ever approved for Alzheimer's disease, launched in 1993 under the name Cognex and proof-of-concept that the cholinergic hypothesis (that boosting acetylcholine could meaningfully help Alzheimer's symptoms) actually worked in the clinic, opening the door for donepezil, rivastigmine, and galantamine to follow. That legacy came with a real cost; tacrine caused liver-enzyme elevations in roughly a quarter to half of treated patients, serious enough that trial protocols required stopping the drug if ALT rose above three times normal, and while the injury was almost always reversible on discontinuation, the burden of mandatory liver monitoring made tacrine impractical once safer, twice-a-day alternatives without the hepatotoxicity reached the market. Its manufacturer discontinued marketing tacrine in the United States in 2013, quietly retiring the drug that had started the entire cholinesterase-inhibitor era.
TAK-071 is Takeda's M1 muscarinic positive allosteric modulator, built around a deliberately low cooperativity value on the finding that cooperativity, not potency, is what decides whether an M1 drug causes diarrhoea; it reached a phase 2 crossover trial in Parkinson disease where it missed its gait endpoint and improved a secondary cognitive measure.
Talsaclidine is a functionally M1-preferring muscarinic agonist developed by Boehringer Ingelheim for Alzheimer's disease; it lowered cerebrospinal fluid amyloid beta in patients but hit dose-limiting sweating and hypersalivation before it reached procognitive doses.
TC-5619 was Targacept's alpha7 nicotinic acetylcholine receptor partial agonist, one of the most closely watched compounds of the alpha7-for-schizophrenia wave that swept through pharma in the early 2010s. An initial exploratory Phase II trial, run as an add-on to quetiapine or risperidone in schizophrenia outpatients, found statistically significant improvement on both a spatial-learning task (the Groton Maze Learning Task) and negative symptoms (SANS), enough of a signal that Targacept and its partner AstraZeneca pushed forward into a much larger, 477-patient, six-country Phase II trial. That bigger confirmatory study failed to replicate the earlier benefit, joining ABT-126, AQW051, and encenicline in the broader collapse of the alpha7 nicotinic hypothesis for schizophrenia cognition; AstraZeneca and Targacept discontinued the program not long after, and Targacept itself later folded into Catalyst Biosciences.
tc299423 is an experimental (targacept) small-molecule nicotinic agonist with an alpha6-preferring profile; it activates alpha6beta2* receptors at ec50 ~30-60 nm (about 2.5-fold over alpha4beta2), is orally bioavailable with a clean off-target screen, produces alpha6*-mediated reward in place-preference tests, but did not block nicotine self-administration; a research tool showing small molecules can preferentially target alpha6*, not a medicine.
Usmarapride is an experimental small-molecule drug that acts as a selective partial agonist of the serotonin 5-HT4 receptor. Developed by Suven Life Sciences under the code SUVN-D4010, it has been studied as a candidate treatment for the cognitive symptoms of Alzheimer's disease and schizophrenia. As of the mid-2020s it had advanced to early-phase clinical testing and is not an approved medicine.
varenicline (chantix/champix) is a cytisine-derived nicotinic partial agonist and a first-line smoking-cessation drug; a high-affinity partial agonist at alpha4beta2 (its core mechanism), full agonist at alpha7, partial at alpha3beta4, and only a weak partial agonist at the alpha6beta2* dopamine-terminal receptors that gate nicotine reward; effective for quitting, with nausea as the main trade-off.
Velnacrine is the main liver metabolite of tacrine, and Hoechst-Roussel developed it under the name Mentane hoping that using the metabolite directly, rather than relying on the body to convert tacrine into it, might dodge tacrine's notorious liver-toxicity problem. It did not; clinical trials found the same pattern of asymptomatic but concerning liver-enzyme elevations that had plagued tacrine, and researchers built a statistical risk model (called PROPP) just to try to predict which Alzheimer's patients would develop hepatotoxicity before exposing them to the drug. Hoechst-Roussel ultimately dropped velnacrine after regulators would not approve it on the safety data submitted, a case of a cleaner metabolite turning out to share its parent drug's core problem.
VU0467154 is a preclinical positive allosteric modulator of the M4 muscarinic receptor, built at Vanderbilt as an in vivo tool compound, and it is the molecule most of the rodent evidence for the M4 antipsychotic hypothesis actually rests on.
VU0486846 is an experimental M1 muscarinic acetylcholine receptor positive allosteric modulator (an "M1 PAM"; it makes the M1 receptor respond more strongly to the brain's own acetylcholine rather than switching it on directly). It came out of the Vanderbilt neuroscience drug-discovery group and is prized as a "clean" research tool: it improves cognition in animal models without the agonist activity, seizures, and classic cholinergic side effects that plagued earlier M1 activators. It has been studied mostly in models of Alzheimer's disease, schizophrenia-related cognitive deficits, prion neurodegeneration, and Rett syndrome. It is a research compound with no human data.
VU319 is a Vanderbilt-discovered M1-selective positive allosteric modulator with minimal intrinsic agonist activity that completed a first-in-human single ascending dose trial without the cholinergic adverse effects that ended earlier compounds in the class.
An M1/M4-preferring muscarinic agonist that failed as an Alzheimer's drug in the 1990s and returned in 2024 as the active antipsychotic half of Cobenfy, the first schizophrenia treatment approved without dopamine receptor blockade.
AF710B, also known as ANAVEX 3-71 (later ANAVEX3-71), is an experimental small-molecule drug that acts as a selective allosteric agonist of the M1 muscarinic acetylcholine receptor and an agonist of the sigma-1 receptor. Originating from the medicinal-chemistry work of Abraham Fisher and developed by Anavex Life Sciences, it has been investigated as a potential disease-modifying treatment for Alzheimer's disease and related neurodegenerative and psychiatric conditions.
